Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Litton

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Frontiers in Artificial Intelligence|August 29, 2022
Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast CancerEhsan Irajizad, Ranran Wu, Jody Vykoukal, et al.
Academic Radiology|July 17, 2021
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRosalind P Candelaria, David A Spak, Gaiane M Rauch, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
NPJ Breast Cancer|June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancerBruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014Mary B Daly, Robert Pilarski, Jennifer E Axilbund, et al.
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
JCO Precision Oncology|December 18, 2025
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Frontiers in Artificial Intelligence|August 29, 2022
Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast CancerEhsan Irajizad, Ranran Wu, Jody Vykoukal, et al.
Academic Radiology|July 17, 2021
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRosalind P Candelaria, David A Spak, Gaiane M Rauch, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
NPJ Breast Cancer|June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancerBruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014Mary B Daly, Robert Pilarski, Jennifer E Axilbund, et al.
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
JCO Precision Oncology|December 18, 2025
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
Pageof 3